

Online Supplementary Material

Cost per Response of Acthar® Gel vs Standard of Care for the Treatment of Proteinuria in Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy Among Adults from the US Healthcare Perspective. *JHEOR*. 2025;12(2):50-61. [doi:10.36469/jheor.2025.142078](https://doi.org/10.36469/jheor.2025.142078)

Table S1: Cost Breakdown at 2 and 3 Years from a US Payer Perspective

Table S2: Incremental Cost per Response from a US Payer Perspective

Figure S1: Scatterplot Acthar® Gel vs Cyclophosphamide and Rituximab Over 1 Year from a US Payer Perspective

This supplementary material has been provided by the authors to give readers additional information about their work.



Table S1. Cost Breakdown at 2 and 3 Years from a US Payer Perspective

Cost Components ^{a,b}	Acthar Gel®, \$	Cyclophosphamide, \$	Rituximab, \$
2 years			
Drug acquisition	172 803	11 578	116 173
Administration/monitoring	0	8 112	11 436
Adverse events	0	69 383	54 329
Other treatments ^c	34 490	172 139	59 005
Disease management ^d	17 244	29 111	33 916
Renal failure management ^e	74 134	88 532	106 540
3 years			
Drug acquisition	167 171	14 549	141 463
Administration/monitoring	0	10 193	13 926
Adverse events	0	87 185	66 156
Other treatments ^c	48 067	225 886	85 388
Disease management ^d	23 654	40 246	46 906
Renal failure management ^e	127 883	162 164	196 204

Abbreviation: iMN, idiopathic membranous nephropathy.

^aResults are presented on a per-person basis

^bAll costs inflated to 2025 United States Dollars

^cOther treatments include immunosuppressants (including monitoring and serious adverse events costs), supportive care treatments (antihypertensives, anticoagulants, and statins), plasmapheresis, pain medications, antidepressants

^dDisease management includes iMN-related inpatient and outpatient (physician office visits, emergency department, other outpatient)

^eRenal failure management includes disease progression costs, including dialysis, renal transplant, and complications


Table S2. Incremental Cost per Response from a US Payer Perspective

Time Frame and Intervention	Incremental Costs, \$ ^{a,b,c}	Incremental Response, %	Incremental Cost per Response, \$ ^{a,b}
1 year			
Acthar Gel® vs cyclophosphamide	17 796	22.9	77 712
Acthar Gel® vs rituximab	18 128	33.0	54 933
2 years			
Acthar Gel® vs cyclophosphamide	-80 184	21.1	Dominant
Acthar Gel® vs rituximab	-82 728	31.1	Dominant
3 years			
Acthar Gel® vs cyclophosphamide	-173 448	22.9	Dominant
Acthar Gel® vs rituximab	-183 268	31.9	Dominant

^aAll costs inflated to 2025 US dollars.

^bResults are presented on a per-person basis.

^cNegative incremental costs indicate that Acthar Gel® is cost-saving.

Figure S1. Scatterplot Acthar® Gel vs Cyclophosphamide and Rituximab Over 1 Year from a US Payer Perspective

Abbreviations: USD, US dollars; WTP, willingness to pay.

Note: Willingness-to-pay threshold of \$150 000 per response.